29 May 2025 in Cardiovascular Research
Transcriptional regulation is essential for the development, homeostasis, and function of all organisms. Transcription factors and epigenetic modifiers play an indispensable role by direct or indirect interaction with DNA or chromatin. Although the role of transcription factor PRDM16 in adipose, haematopoietic, skeletal, and neural cell lineage specification is well-documented, its function within the cardiovascular system has only recently gained significant attention. Similar as in adipose tissue, PRDM16 displays an asymmetric expression pattern within the cardiovascular system, where it is exclusively expressed by ventricular cardiomyocytes and endothelial and smooth muscle cells of arteries while being absent in their atrial and venous counterparts. Concordantly, an increasing number of clinical and preclinical studies have identified PRDM16 as an important multi-modal regulator of cardiovascular development and function. Moreover, aberrant PRDM16 expression has now been linked to (cardio)vascular diseases, including left ventricular non-compaction, migraine, and coronary artery disease. In this review, we give a synopsis of PRDM16's expression and function within (developing) cardiovascular tissues and provide insights into how impaired PRDM16 signalling contributes to cardiovascular disease.
1 April 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
BACKGROUND: TF (transcription factor) Prdm16 (positive regulatory domain–containing protein 16) regulates hematopoietic and neuronal stem cell homeostasis, adipose differentiation, and cardiac development. Its role in the circulatory system extends beyond the heart, as Prdm16 loss in arterial endothelial cells (ECs) impairs arterial reperfusion of ischemic mouse limbs due to endothelial dysfunction, and PRDM16 polymorphisms are associated with coronary artery disease. METHODS: Zebrafish were used to analyze vascular development, arteriovenous endothelial specification, and the emergence of arteriovenous malformations in the absence or presence of Prdm16 or Notch signaling. Lentiviral-mediated Prdm16 overexpression in human endothelial (progenitor) cells was coupled to qRT-PCR (real-time quantitative polymerase chain reaction), Western blot, and transcriptional profiling to document Prdm16’s importance for arterial lineage specification. Coimmunoprecipitation in HEK293 (human embryonic kidney 293) cells was performed to assess physical interaction between Prdm16 and the Notch pathway. Existing mouse and human data sets were reanalyzed to evaluate Prdm16 expression in mammalian arteriovenous malformations. RESULTS: Prdm16 actively promotes arterial EC identity while suppressing venous fate. Like in mice, Prdm16 is expressed by arterial ECs early during vascular development in zebrafish, where it synergistically coordinates arterial development together with canonical notch signaling, as their combined loss in zebrafish leads to arteriovenous malformations. PRDM16’s arterializing effect on human ECs is dependent on canonical Notch activity, as it is blunted in the presence of canonical Notch inhibitors and potentiated in the presence of delta-like ligand 4. Mechanistically, Prdm16 does not increase the protein levels of the cleaved intracellular domain of Notch receptors (notch intracellular domain) but rather potentiates the effect of the latter via physical and functional interaction. Prdm16 further finetunes Notch signaling and arterial development by complexing with Hey2 (Hes-related family bHLH TF with YRPW motif 2), the basic helix-loop-helix TF acting downstream of canonical Notch during arterial lineage specification and development. CONCLUSIONS: Together, our data demonstrate an intricate interplay between Prdm16 and Notch in ECs and indicate that Prdm16 signaling may constitute a novel therapeutic target for arteriovenous malformations.
14 January 2026 in Research Square
Endothelial-to-mesenchymal transition (EndMT) contributes to vascular remodeling and endothelial dysfunction in diseases such as atherosclerosis and pulmonary arterial hypertension. This process describes a gradual shift in which endothelial cells (ECs) lose expression of classical EC markers and acquire mesenchymal-like gene expression patterns and phenotypic traits. Although SMAD transcription factors are key regulators of EndMT, driven by mechanical cues from disturbed flow that activate BMP or TGFβ signaling, their weak DNA-binding affinity invoked the need for additional transcriptional co-factors to specify gene targets under pathophysiological flow conditions. Here, we identified FOXO1 as a transcriptional co-factor that cooperates with SMADs to regulate mesenchymal gene expression in ECs exposed to irregular flow. FOXO1 and SMADs co-occupy genomic loci and form transcriptional complexes. Although SMAD DNA binding is FOXO1-independent, FOXO1 activity is required for full induction of SMAD target genes. Notably, FOXO1 DNA-binding activity is essential for robust activation of EndMT-associated genes, as both pharmacological inhibition and siRNA-mediated depletion of FOXO1 attenuate SMAD target gene expression. Functionally, combined targeting of FOXO1 and SMAD signaling rescues EndMT-associated endothelial dysfunction in carotid arteries of mice. Our results describe FOXO1 as key integrator of SMAD-mediated EndMT signaling, linking it to pathogenic SMAD activation in disease contexts.